MANE — Veradermics, Inc
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1827635 ·
Last close
$119.60
Market Cap
$5.00B
52W High
$131.24
52W Low
$65.80
ADV30
675,596
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -29,713,000 | -27,232,000 | 397,356,000 | 168,412,000 | 6,716,000 |
| Dec 2025 | 0 | — | -22,753,000 | -21,847,000 | 152,619,000 | 21,766,000 | 273,633,000 |
| Sep 2025 | — | — | — | — | 18,797,000 | 5,660,000 | 114,812,000 |
| Mar 2025 | 0 | — | -12,882,000 | -12,400,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-61,745,000
Investing CF
$-226,827,000
Financing CF
$477,354,000
CapEx
$-24,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.68
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-150,653,000
Inventory
—
Receivables
$1,651,000
ST Investments
$222,385,000
EBIT TTM
$-69,810,000
Pretax Income TTM
$-67,139,000
Interest Exp TTM
$292,000
Analysts
4
Annual Trend (SEC EDGAR, last 3y)
Revenues vs Net Income (last 3y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -71,557,000 | -69,995,000 | 152,619,000 | 273,633,000 | — | -71,602,000 |
| Dec 2024 | 0 | -26,384,000 | -26,488,000 | 55,535,000 | 104,015,000 | — | -23,688,000 |
| Dec 2023 | 0 | -17,324,000 | -16,490,000 | 17,562,000 | 39,804,000 | — | -13,510,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-3.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| TNGX | Tango Therapeutics, Inc. | $5.06B | $31.06 | — |
| EWTX | Edgewise Therapeutics, Inc. | $4.89B | $45.41 | — |
| INDV | Indivior Pharmaceuticals, Inc. | $4.79B | $40.50 | — |
| ORKA | Oruka Therapeutics, Inc. | $5.23B | $86.79 | — |
| LEGN | Legend Biotech Corp | $5.24B | $27.08 | — |
News headlines (Yahoo Finance, 1h cache)
Can Veradermics (MANE) Climb 27.65% to Reach the Level Wall Street Analysts Expect?
2026-06-24 13:55 · Yahoo
Is Veradermics, Incorporated (MANE) A Good Stock To Buy Now?
2026-06-19 16:24 · Yahoo
Achieve Life Sciences Appoints Jeffrey Farrow and Reid Waldman, MD to Board of Directors
2026-06-02 12:30 · Yahoo
Viking Stake In Veradermics Highlights Risky Growth And Ownership Shifts
2026-05-21 06:09 · Yahoo
Here is Why Veradermics (MANE) is One of the Best Performing NYSE Stocks So Far in 2026
2026-05-21 03:02 · Yahoo
The IPO Boom Isn’t in Tech and AI—Yet
2026-05-15 08:52 · Yahoo
Citi Remains Bullish on Veradermics, Incorporated (MANE)
2026-05-10 23:12 · Yahoo
MANE Study 302: Veradermics Posts Positive Top-Line Phase II/III Results for Oral Minoxidil Pill
2026-05-03 16:02 · Yahoo
Veradermics (MANE) Reports Positive Phase 2/3 Results for Male Pattern Hair Loss Treatment VDPHL01
2026-04-30 13:57 · Yahoo
Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains
2026-04-29 09:46 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.